ITGAM and neoplasm: In a dual‐tumor immunocompetent mouse model, Lee and colleagues observed the activation of Tregs in conjunction with CD11b+ monocytes within the tumor, which contributes significantly to the diminished efficacy of antiprogrammed death‐ligand 1 (PD‐1) treatments.100